• Publications
  • Influence
Natural history of progression after PSA elevation following radical prostatectomy.
Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy, and these data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies. Expand
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent and it may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies. Expand
The development of human benign prostatic hyperplasia with age.
The prevalence and growth rate of human benign prostatic hyperplasia with age is reported by combining and analyzing data from 10 independent studies containing more than 1,000 prostates. Expand
NCCN clinical practice guidelines in oncology: prostate cancer.
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
Clinical parameters can help risk stratify patients for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy to enroll them in early aggressive treatment trials, and highlight that survival in low-risk patients can be quite prolonged. Expand
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
The probability of organ-confined disease improved across the groups, and further stratification of the Gleason score and PSA level allowed better differentiation of individual patients. Expand
Mendelian inheritance of familial prostate cancer.
Evidence is provided that prostate cancer is inherited in Mendelian fashion in a subset of families and provide a foundation for gene mapping studies of heritable prostate cancer. Expand
Radical prostatectomy versus watchful waiting in early prostate cancer.
  • P. Walsh
  • Medicine
  • The Journal of urology
  • 1 October 2005
The absolute reduction in the risk of death after 10 years is small, but the reductions in the risks of metastasis and local tumor progression are substantial. Expand
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
A second genetic variant in the 8q24 region that, in conjunction with another variant recently discovered, accounts for about 11%–13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans is reported. Expand